GlassScriptPhysician profile
Marsha A Smith
NPI 1346324100
$7,591.01
in general payments reported to CMS, 2019-2025
41 companies · $620 in 2025
The $620 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,542 · 2022: $2,212 · 2023: $2,166 · 2024: $1,051 · 2025: $620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,837.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,445.15 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $869.32 | 2021-2024 | Trelegy Ellipta |
| Lilly USA, LLC | $849.04 | 2021-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $748.45 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $406.87 | 2021-2024 | |
| Amgen INC. | $297.19 | 2023-2024 | Repatha, Otezla |
| Abbvie INC. | $210.91 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $177.68 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $165.73 | 2022-2023 | Quviviq |
| Astellas Pharma US INC | $134.06 | 2021-2023 | Myrbetriq |
| Merck Sharp & Dohme LLC | $130.35 | 2021-2023 | Steglatro, Belsomra |
| Genzyme Corporation | $123.93 | 2023 | |
| Supernus Pharmaceuticals, INC. | $122.88 | 2024 | Qelbree |
| Horizon Therapeutics Plc | $122.88 | 2022 | |
| Renalytix Ai, INC. | $121.67 | 2023-2024 | Kidneyintelx Blood Collection Convenience Kit |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marsha Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.